This may be explained by the fact that most of the patients in our study (84.7%) had stage I lung adenocarcinoma and early stage tumors are reported to have fewer TP53 mutations than advanced-stage tumors [35]. The gene discussed is TP53; the disease is lung adenocarcinoma.